.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Citi
Fish and Richardson
Chinese Patent Office
Cipla
Merck
Medtronic
Cantor Fitzgerald
Teva
Johnson and Johnson

Generated: July 25, 2017

DrugPatentWatch Database Preview

Mometasone furoate - Generic Drug Details

« Back to Dashboard

What are the generic sources for mometasone furoate and what is the scope of mometasone furoate freedom to operate?

Mometasone furoate
is the generic ingredient in five branded drugs marketed by G And W Labs, Glenmark Generics, Fougera Pharms, Taro, Merck Sharp Dohme, Apotex Inc, Perrigo New York, Perrigo Israel, Tolmar, and Amneal Pharms, and is included in twenty-five NDAs. There are six patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Mometasone furoate has thirty-four patent family members in twenty-six countries.

There are twenty-nine drug master file entries for mometasone furoate. Nineteen suppliers are listed for this compound.

Summary for Generic Name: mometasone furoate

Tradenames:5
Patents:6
Applicants:10
NDAs:25
Drug Master File Entries: see list29
Suppliers / Packagers: see list19
Bulk Api Vendors: see list45
Clinical Trials: see list226
Patent Applications: see list5,410
Therapeutic Class:Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal)
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:mometasone furoate at DailyMed

Pharmacology for Ingredient: mometasone furoate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme
ASMANEX TWISTHALER
mometasone furoate
POWDER;INHALATION021067-002Feb 1, 2008RXYesNo► Subscribe► SubscribeY► Subscribe
Glenmark Generics
MOMETASONE FUROATE
mometasone furoate
LOTION;TOPICAL090506-001Aug 9, 2010ABRXNoNo► Subscribe► Subscribe► Subscribe
Merck Sharp Dohme
ELOCON
mometasone furoate
LOTION;TOPICAL019796-001Mar 30, 1989ABRXYesYes► Subscribe► Subscribe► Subscribe
Perrigo New York
MOMETASONE FUROATE
mometasone furoate
OINTMENT;TOPICAL076067-001Mar 18, 2002ABRXNoNo► Subscribe► Subscribe► Subscribe
Glenmark Generics
MOMETASONE FUROATE
mometasone furoate
OINTMENT;TOPICAL078571-001May 28, 2008ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: mometasone furoate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme
ASMANEX HFA
mometasone furoate
AEROSOL, METERED;INHALATION205641-002Apr 25, 2014► Subscribe► Subscribe
Merck Sharp Dohme
ASMANEX TWISTHALER
mometasone furoate
POWDER;INHALATION021067-002Feb 1, 2008► Subscribe► Subscribe
Merck Sharp Dohme
NASONEX
mometasone furoate
SPRAY, METERED;NASAL020762-001Oct 1, 1997► Subscribe► Subscribe
Merck Sharp Dohme
ASMANEX TWISTHALER
mometasone furoate
POWDER;INHALATION021067-002Feb 1, 2008► Subscribe► Subscribe
Merck Sharp Dohme
ASMANEX TWISTHALER
mometasone furoate
POWDER;INHALATION021067-001Mar 30, 2005► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: mometasone furoate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,495,167 Preparation of powder agglomerates► Subscribe
7,687,073Preparation of powder agglomerates► Subscribe
7,387,794Preparation of powder agglomerate► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: mometasone furoate

Country Document Number Estimated Expiration
Poland185384► Subscribe
Austria216903► Subscribe
Brazil9707660► Subscribe
Norway316787► Subscribe
Germany69712324► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: MOMETASONE FUROATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0002Belgium► SubscribePRODUCT NAME: MOMETASONE FUROATE; NAT. REGISTRATION NO/DATE: NL 19601 19950919; FIRST REGISTRATION: GR - 10681/89 19900622
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Merck
Accenture
Johnson and Johnson
Fuji
QuintilesIMS
Farmers Insurance
US Department of Justice
US Army
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot